Last reviewed · How we verify
NCT07239375
Intraosseous Infusion in Hematologic Critical Patients
trial testing intra-osseous (IO) infusion needle/catheter in Intraosseous Infusions in 52 participants. Currently enrolling.
22 October 2027
Quick facts
| Lead sponsor | Shanxi Bethune Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 52 |
| Start date | 22 November 2025 |
| Primary completion | 22 October 2027 |
| Estimated completion | 23 October 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- intra-osseous (IO) infusion needle/catheter
Conditions studied
- Intraosseous Infusions — all drugs for Intraosseous Infusions →
Sponsor
Shanxi Bethune Hospital
Who can join
Adults 18 to 65, any sex, with Intraosseous Infusions. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This single-center, prospective observational study will enroll 52 critically hematology patients aged 18-65 years including agranulocytosis, thrombocytopenia, severe anemia, advanced tumors, septic shock, sepsis DIC、 severe gastrointestinal bleeding, involvement of the central nervous system or intracranial hemorrhage, patients undergoing hematopoietic stem cell transplantation，etc. Vascular access will be established via intraosseous (IO) needle placement, primarily to evaluate first-attempt puncture success rate, therapeutic efficacy, and overall survival rate. Secondary endpoints include infusion speed, hemodynamic improvement, and procedural complications such as local infection and fat embolism. The study aims to definitively assess the efficacy and safety of IO infusion as a rapidly established, "non-collapsible" alternative vascular access route in the hematologic intensive care setting.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07239375
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Shanxi Bethune Hospital trials
Trials by the same sponsor.
- NCT07371533 — Clinical Study of Recombinant Anti-CD19m-CD3 Antibody Injection (A-319) · NA · not yet recruiting
- NCT07514052 — Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study · recruiting
- NCT07497165 — Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma · recruiting
- NCT07265037 — Integrated TCM - Western Medicine Strategy for Long - Distance Diabetes Management · NA · recruiting
- NCT07204522 — Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients. · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07239375 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanxi Bethune Hospital
- Last refreshed: 20 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07239375.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing